Metabolic Disorders News and Research

RSS

Long-term cola intake weakens immune cell counts in controlled rat study

Replacing drinking water entirely with sugar-sweetened or sugar-free cola for eight weeks altered gut microbiota composition and immune-related indices in rats, despite no changes in body weight or blood glucose. Both beverages were associated with leukocyte reductions and organ-related biochemical shifts, with sugar-sweetened cola more strongly linked to renal markers and diet cola to elevated liver enzymes.

25 Feb 2026

Tirzepatide activates brown fat, boosting metabolism beyond appetite control

Tirzepatide is one of the drugs that has revolutionized the treatment of obesity and other conditions such as diabetes in recent years.

24 Feb 2026

Swiss centenarians show youthful blood protein profiles in aging study

In Switzerland, 0.02% of the population lives beyond the age of 100. Could there be biological characteristics associated with this exceptional longevity? As part of the "SWISS100" study, the first large-scale Swiss research project dedicated to centenarians, a team from the University of Geneva (UNIGE) and the University of Lausanne (UNIL) compared the blood profiles of centenarians with those of octogenarians, and then with those of individuals aged 30 to 60.

24 Feb 2026

New 3D liver reconstructions show how cirrhosis reshapes organ architecture

Never-before-seen 3D reconstructions of human liver tissue have been created at a cellular level. The details obtained by a team of UW Medicine and University of Washington engineers and physicians capture the spatial microstructure of multiple lobes of this multitasking organ.

23 Feb 2026

Combining gene and biomarker screening for newborn health

For more than six decades, biomarker-based newborn screening has played a pivotal role in reducing infant mortality and long-term disability by enabling early detection of metabolic and endocrine disorders.

23 Feb 2026

Insilico Medicine and MSK collaborate to discover new drug targets for gastroesophageal malignancies

Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and Memorial Sloan Kettering Cancer Center (MSK) have entered into a collaborative research agreement aimed at discovering new therapeutic targets for gastroesophageal malignancies.

17 Feb 2026

Study examines the relationship between leukocyte telomere length and age-related cataract

Cataracts remain the leading cause of blindness worldwide among adults over 50, despite major advances in surgical treatment.

12 Feb 2026

Inhibiting PTP1B protein improves memory in Alzheimer’s disease models

Alzheimer's disease is often measured in statistics: millions affected worldwide, cases rising sharply, costs climbing into the trillions.

5 Feb 2026

Why the carnivore diet’s claimed benefits don’t outweigh its health risks

Researchers determine the nutritional adequacy and health effects of the carnivore diet.

2 Feb 2026

Insilico Medicine and Qilu Pharmaceutical partner to develop AI-designed cardiometabolic drugs

Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, and Qilu Pharmaceutical Group, a major comprehensive modern pharmaceutical enterprise in China, as well as its subsidiary Shanghai Qilu Pharmaceutical Research Center, today announced a strategic partnership on innovative drug development, leveraging Insilico's proprietary Pharma.AI platform to jointly develop small molecule inhibitors, focusing on specific targets for cardiometabolic disease management.

27 Jan 2026

Midlife insulin levels influence timing and duration of menopausal vasomotor symptoms

A woman's insulin levels in midlife are linked to the timing and duration of menopausal hot flashes, night sweats and cold sweats, according to new research from the University of Victoria (UVic).

27 Jan 2026

New role for GLP-1 drugs: Improving survival in people with severe psychiatric disorders

This editorial argues that GLP-1 receptor agonists could substantially improve healthspan and reduce premature mortality in people with serious mental illnesses by targeting cardiometabolic risk rather than psychiatric symptoms alone. It highlights emerging evidence, safety considerations, and equity challenges that position GLP-1 RAs as a promising public health strategy for this high-risk population.

25 Jan 2026

AI-designed NLRP3 inhibitor receives FDA clearance for Parkinson disease trials

Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), today announced that ISM8969, an orally available NLRP3 inhibitor targeting inflammation and neurodegenerative disorders, has recently received investigational new drug (IND) clearance from the U.S. Food and Drug Administration (FDA), intended for the treatment of Parkinson's Disease.

23 Jan 2026

Sperm RNA aging shift that may explain paternal age effects

Study reveals an 'aging cliff' in sperm RNA, linking age-related changes to early development and highlighting risks associated with advanced paternal age.

22 Jan 2026

Dr Adam Davenport appointed as CSO to strengthen leadership in integrated drug discovery

We are pleased to announce the appointment of Dr Adam Davenport as Chief Scientific Officer to spearhead our integrated drug discovery offering for biotech and pharmaceutical partners.

From Concept Life Sciences 19 Jan 2026

Researchers discover how Mycoplasma pneumoniae acquires cholesterol from human hosts

A multidisciplinary team has uncovered a key mechanism that allows the human bacterium Mycoplasma pneumoniae-responsible for atypical pneumonia and other respiratory infections-to obtain cholesterol and other essential lipids directly from the human body.

16 Jan 2026

Metabolic Disorders News and Research

Long-term cola intake weakens immune cell counts in controlled rat study

Tirzepatide activates brown fat, boosting metabolism beyond appetite control

Swiss centenarians show youthful blood protein profiles in aging study

New 3D liver reconstructions show how cirrhosis reshapes organ architecture

Combining gene and biomarker screening for newborn health

Insilico Medicine and MSK collaborate to discover new drug targets for gastroesophageal malignancies

Study examines the relationship between leukocyte telomere length and age-related cataract

Inhibiting PTP1B protein improves memory in Alzheimer’s disease models

Why the carnivore diet’s claimed benefits don’t outweigh its health risks

Insilico Medicine and Qilu Pharmaceutical partner to develop AI-designed cardiometabolic drugs

Midlife insulin levels influence timing and duration of menopausal vasomotor symptoms

New role for GLP-1 drugs: Improving survival in people with severe psychiatric disorders

AI-designed NLRP3 inhibitor receives FDA clearance for Parkinson disease trials

Sperm RNA aging shift that may explain paternal age effects

Dr Adam Davenport appointed as CSO to strengthen leadership in integrated drug discovery

Researchers discover how Mycoplasma pneumoniae acquires cholesterol from human hosts

New oral drug safely lowers triglycerides and other blood lipids in Phase 1 trial

Blocking liver enzyme Caspase-2 may increase long-term cancer risk

Natural daylight during office hours improves glucose stability in type 2 diabetes

Why promising microbiome therapies rarely work in patients

eBook: Integrated solutions for metabolic disease drug development eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News